Number of shares and voting rights of Innate Pharma as at March 24, 2014
R&D Update on April 10, 2014 in New York
Number of shares and voting rights of Innate Pharma as at March 7, 2014
Innate Pharma continues Phase II trial with lirilumab as planned, following Data and Safety Monitoring Board recommendation
Innate Pharma to hold its annual general meeting of shareholders on March 27, 2014
Number of shares and voting rights of Innate Pharma as at February 10, 2014
Annual results for 2013: Cash position strengthened to €41.3m as at December 31, 2013
Innate Pharma acquires full rights to ANTI-NKG2A checkpoint inhibitor from Novo Nordisk A/S
Innate Pharma announces its financial calendar for 2014 as well as its participation to upcoming investor conferences
Full-year report on Innate Pharma’s liquidity contract with Gilbert Dupont
